Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Health systems and care delivery

Topic: Risk, prevention and care in population studies

Plain-language summary

Overall, 1.45% of the study cohort age ≥65 received HBMC. Compared to No HBMC (n = 132,147), those receiving HBMC (n = 38,800) were more likely to be: older (46.6% vs. 11.9% age 85+); female (70.8% vs. 58.5%); Black (12.3% vs. 11.3%); urban (90.3% vs. 81.3%); experience hospitalization (38.0% vs. 13.3%), emergency department visit (58.3% vs. 26.9%), ambulance trip (44.1% vs. 9.6%), skilled nursing facility (37.6% vs. 6.4%), or hospice care admission (21.1% vs. 3.5%). They also were more likely to experience a wide range of chronic conditions including dementia (58.1% vs. 5.2%), morbidity burden (Charlson score 3.4 vs. 1.8), and serious illness (77.1% vs. 29.5%). All comparisons p < 0.0001. MA beneficiaries who received HBMC are older, experience greater chronic and serious illness burden, and higher levels of facility-based care than those who did not receive HBMC. MA plans need strategies to identify patients that would benefit from HBMC and develop approaches to deliver such care to this impactful, often invisible population.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 132,147 participants. This study describes characteristics of Medicare Advantage beneficiaries who receive home-based medical care, finding they are older and have more chronic and serious illness including dementia. Reported effect size: 1.45%; 46.6%; 11.9%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Leff, B. A., Ritchie, C. S., Ciemins, E. L., & Dunning, S. C. (2022). Prevalence of use and characteristics of users of home‐based medical care in Medicare Advantage. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.18085

Vancouver

Leff BA, Ritchie CS, Ciemins EL, Dunning SC. Prevalence of use and characteristics of users of home‐based medical care in Medicare Advantage. Journal of the American Geriatrics Society. 2022. doi:10.1111/jgs.18085. PMID: 36222194.

BibTeX

@article{leff2022-36222194,
  author  = {Leff, Bruce A. and Ritchie, Christine Seel and Ciemins, Elizabeth L. and Dunning, Stephan C.},
  title   = {{Prevalence of use and characteristics of users of home‐based medical care in Medicare Advantage}},
  journal = {Journal of the American Geriatrics Society},
  year    = {2022},
  doi     = {10.1111/jgs.18085},
  pmid    = {36222194},
  url     = {https://doi.org/10.1111/jgs.18085}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This study describes characteristics of Medicare Advantage beneficiaries who receive home-based medical care, finding they are older and have more chronic and serious illness including dementia. It does not test any treatment, cure, or prevention for Alzheimer's disease, and it suggests Medicare Advantage plans need strategies to identify patients who would benefit from home-based care.

Study details

How this study scored 60/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 4 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 1 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record 3 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 60 of 100.60 of 100 points earned40 not earned

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of the American Geriatrics Society)
Journal's citation record 3 / 4 Journal of the American Geriatrics Society: journal h-index 344 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2022 — within 6 year(s) of the newest study here
Sample size 4 / 4 132,147 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 13 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 2.2 citations a year over 6 year(s) since 2022
Impact for its field and year 2 / 6 Cited 2.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 2 other studies in this library
Still being cited 1 / 4 Cited 11 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Stephan C. Dunning: h-index 21 (OpenAlex, whole career)
Institution's track record 3 / 3 Harvard University: institution h-index 3,235 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 36222194)
Free to read 2 / 2 Free to read
Total 60 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Health systems and care delivery from nearby years

Also tagged “palliative”

858 studies in the library carry the topic tag “palliative”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 858 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Health systems and care delivery

See all studies in Health systems and care delivery →